ConductScience.org, home

Paper37499080

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact.

Scott AB and 2 others. Medicine (Baltimore), 2023. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact. Papers, record 37499080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37499080

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact.
PubMed
Journal
Medicine (Baltimore)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
2.64
iCite
Revised in PubMed
2023-07-31
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Scott ABAlan B
2Fahn SStanley
3Brin MFMitchell F

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Botulinum Toxins, Type AMajor topic
BlepharospasmMajor topic
StrabismusMajor topic
Humans
Activities of Daily Living
Quality of Life

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07180394Botulinum Toxin for Strabismus TreatmentBackground

Source ClinicalTrials.gov

Download CSV of trials

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122234840History of the 'geste antagoniste' sign in cervical dystonia.J Neurol2012https://conductscience.org/library/papers/22234840PubMed
224786379Sustained improvement of reading symptoms following botulinum toxin A injection for convergence insufficiency.Strabismus2014https://conductscience.org/library/papers/24786379PubMed
317212988Botulinum toxin in ophthalmology.Surv Ophthalmol2007https://conductscience.org/library/papers/17212988PubMed
423380701Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.Toxicon2013https://conductscience.org/library/papers/23380701PubMed
512465070Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord2002https://conductscience.org/library/papers/12465070PubMed
61579114Properties and use of botulinum toxin and other microbial neurotoxins in medicine.Microbiol Rev1992https://conductscience.org/library/papers/1579114PubMed
76838174Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.Ann Neurol1983https://conductscience.org/library/papers/6838174PubMed
81845036Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, November 12-14, 1990.Arch Neurol1991https://conductscience.org/library/papers/1845036PubMed
931012389Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis.Strabismus2019https://conductscience.org/library/papers/31012389PubMed
1011835433Epidemiology of primary blepharospasm.Mov Disord2002https://conductscience.org/library/papers/11835433PubMed
117243198Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.Ophthalmology1980https://conductscience.org/library/papers/7243198PubMed
1218458230
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology2008https://conductscience.org/library/papers/18458230PubMed
1328186662Blepharospasm 40 years later.Mov Disord2017https://conductscience.org/library/papers/28186662PubMed
1427064462Blepharospasm: Update on Epidemiology, Clinical Aspects, and Pathophysiology.Front Neurol2016https://conductscience.org/library/papers/27064462PubMed
156363970Cranial dystonia: double-blind crossover study of anticholinergics.Neurology1984https://conductscience.org/library/papers/6363970PubMed
163977705Botulinum A toxin injection as a treatment for blepharospasm.Arch Ophthalmol1985https://conductscience.org/library/papers/3977705PubMed
177991136Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology1994https://conductscience.org/library/papers/7991136PubMed
1831025814The Danish Rural Eye Study: prevalence of strabismus among 3785 Danish adults - a population-based cross-sectional study.Acta Ophthalmol2019https://conductscience.org/library/papers/31025814PubMed
197236103Blepharospasm surgery. An anatomical approach.Arch Ophthalmol1981https://conductscience.org/library/papers/7236103PubMed
2019648904Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.Eye (Lond)2010https://conductscience.org/library/papers/19648904PubMed

See all 35 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42180227Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms.Front Neurol2026https://conductscience.org/library/papers/42180227PubMed
41584320High Dose AbobotulinumtoxinA for Blepharospasm: A Case Report on the Safety and Efficacy of 500 Units of AbobotulinumtoxinA.Tremor Other Hyperkinet Mov (N Y)2026https://conductscience.org/library/papers/41584320PubMed
40002825Botulinum Neurotoxins as Two-Faced Janus Proteins.Biomedicines2025https://conductscience.org/library/papers/40002825PubMed
39803022Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review.Cureus2024https://conductscience.org/library/papers/39803022PubMed
38601787Diplopia Secondary to Neurotoxin Injections: Prevention, Diagnosis, and Management.J Clin Aesthet Dermatol2024https://conductscience.org/library/papers/38601787PubMed
38393175From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction.Toxins (Basel)2024https://conductscience.org/library/papers/38393175PubMed
37499079The pluripotential evolution and journey of Botox (onabotulinumtoxinA).Medicine (Baltimore)2023https://conductscience.org/library/papers/37499079PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37499080

GET https://conductscience.org/api/papers/v1/37499080/references?page=2